Alzheimers disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Adults over 35 years of age who complain of cognitive impairment; 2.Able to cooperate in providing tear samples. 3.Able to cooperate with the completion of the Alzheimer's disease diagnosis process. Biomarkers of Alzheimer's disease include blood ptau217 rise/CSFAß42/40 or Aß42 decline with or without ptau181 and total tau/Aß-PET-CT suggesting amyloid deposition in brain tissue; 4.It can be used in conjunction with other clinical and imaging examinations; 5.The patient or their family member signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Unable to cooperate with the examination staff. 2.Patients with cognitive impairment secondary to central nervous system infections (such as HIV, neurosyphilis, autoimmune encephalitis) or systemic diseases (such as diabetes, thyroid dysfunction); 3.Patients with cognitive impairment secondary to ocular diseases that may affect tear biochemical parameters (including ocular infections, ocular inflammation, or other acute ocular diseases); 4.Patients with significant dysfunction of major organs such as the heart, lungs, liver, or kidneys.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ability of tear biomarkers to distinguish between Alzheimer's disease (AD) and non-AD populations (Area Under Curve, AUC);Accuracy;Sensitivity;Specificity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between tear markers and retinal and choroidal OCTA blood flow parameters;Differences in tear marker levels between AD patients and non-AD patients, as well as between patients with varying degrees within the AD group; | — |
Countries
China
Contacts
Zhejiang Provincial People's Hospital